Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for peripheral spondyloarthritis without ankylosing spondylitis or psoriatic arthritis
NL-OMON23446Active, not recruiting
- Sponsor
- Dr. Baeten
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial in peripheral spondyloarthritis (pSpA) comparing Adalimumab then open-label adalimumab with Placebo then open-label adalimumab (2 arms). Primary endpoint: Efficacy and safety of adalimumab. Started Mar 2009; status: active, not recruiting.
02
Drugs
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NL-OMON23446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23446.